Effects of preceding interferon therapy on outcome after surgery for hepatitis C virus-related hepatocellular carcinoma

Yoshito Tomimaru, Hiroaki Nagano, Hidetoshi Eguchi, Shogo Kobayashi, Shigeru Marubashi, Hiroshi Wada, Masahiro Tanemura, Koji Umeshita, Naoki Hiramatsu, Tetsuo Takehara, Yuichiro Doki, Masaki Mori

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background and Objectives: Interferon (IFN) can eradicate hepatitis C virus (HCV)-RNA from serum and hepatic tissue, and suppress the development of hepatocellular carcinoma (HCC). Despite such effectiveness, HCC develops even in HCV patients successfully treated with IFN therapy. Methods: HCV-related HCC patients who underwent curative hepatectomy for HCC were divided into three groups according to preceding IFN for HCV infection therapy and the therapeutic effect: responders group (n=23), non-responders group (n=46), and no-IFN group (n=215). Postoperative outcome was retrospectively examined in the three groups. Results: AST and ALT were significantly lower in responders group than non-responders group (P<0.001, P=0.001) and no-IFN group (P=0.001, P=0.002). Platelet count was significantly higher in responders group than other groups (P=0.008, P=0.001). The percentage of cirrhotic patients in responders group was significantly lower than other groups (P=0.017, P=0.014). Multivariate analysis identified preceding IFN therapy to be associated with disease-free survival at marginal significance (P=0.086), and as a significant independent factor for overall survival (P=0.042). Conclusions: Preceding IFN therapy for HCV infection improves postoperative outcome in HCV-related HCC patients treated successfully with IFN.

Original languageEnglish
Pages (from-to)308-314
Number of pages7
JournalJournal of Surgical Oncology
Volume102
Issue number4
DOIs
Publication statusPublished - Sep 15 2010

Fingerprint

Hepacivirus
Interferons
Hepatocellular Carcinoma
Virus Diseases
Therapeutics
Hepatectomy
Therapeutic Uses
Platelet Count
Disease-Free Survival
Multivariate Analysis
RNA
Survival
Liver
Serum

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

Effects of preceding interferon therapy on outcome after surgery for hepatitis C virus-related hepatocellular carcinoma. / Tomimaru, Yoshito; Nagano, Hiroaki; Eguchi, Hidetoshi; Kobayashi, Shogo; Marubashi, Shigeru; Wada, Hiroshi; Tanemura, Masahiro; Umeshita, Koji; Hiramatsu, Naoki; Takehara, Tetsuo; Doki, Yuichiro; Mori, Masaki.

In: Journal of Surgical Oncology, Vol. 102, No. 4, 15.09.2010, p. 308-314.

Research output: Contribution to journalArticle

Tomimaru, Y, Nagano, H, Eguchi, H, Kobayashi, S, Marubashi, S, Wada, H, Tanemura, M, Umeshita, K, Hiramatsu, N, Takehara, T, Doki, Y & Mori, M 2010, 'Effects of preceding interferon therapy on outcome after surgery for hepatitis C virus-related hepatocellular carcinoma', Journal of Surgical Oncology, vol. 102, no. 4, pp. 308-314. https://doi.org/10.1002/jso.21633
Tomimaru, Yoshito ; Nagano, Hiroaki ; Eguchi, Hidetoshi ; Kobayashi, Shogo ; Marubashi, Shigeru ; Wada, Hiroshi ; Tanemura, Masahiro ; Umeshita, Koji ; Hiramatsu, Naoki ; Takehara, Tetsuo ; Doki, Yuichiro ; Mori, Masaki. / Effects of preceding interferon therapy on outcome after surgery for hepatitis C virus-related hepatocellular carcinoma. In: Journal of Surgical Oncology. 2010 ; Vol. 102, No. 4. pp. 308-314.
@article{2885d8e99c1e4e0ab4bb874f1ae019b7,
title = "Effects of preceding interferon therapy on outcome after surgery for hepatitis C virus-related hepatocellular carcinoma",
abstract = "Background and Objectives: Interferon (IFN) can eradicate hepatitis C virus (HCV)-RNA from serum and hepatic tissue, and suppress the development of hepatocellular carcinoma (HCC). Despite such effectiveness, HCC develops even in HCV patients successfully treated with IFN therapy. Methods: HCV-related HCC patients who underwent curative hepatectomy for HCC were divided into three groups according to preceding IFN for HCV infection therapy and the therapeutic effect: responders group (n=23), non-responders group (n=46), and no-IFN group (n=215). Postoperative outcome was retrospectively examined in the three groups. Results: AST and ALT were significantly lower in responders group than non-responders group (P<0.001, P=0.001) and no-IFN group (P=0.001, P=0.002). Platelet count was significantly higher in responders group than other groups (P=0.008, P=0.001). The percentage of cirrhotic patients in responders group was significantly lower than other groups (P=0.017, P=0.014). Multivariate analysis identified preceding IFN therapy to be associated with disease-free survival at marginal significance (P=0.086), and as a significant independent factor for overall survival (P=0.042). Conclusions: Preceding IFN therapy for HCV infection improves postoperative outcome in HCV-related HCC patients treated successfully with IFN.",
author = "Yoshito Tomimaru and Hiroaki Nagano and Hidetoshi Eguchi and Shogo Kobayashi and Shigeru Marubashi and Hiroshi Wada and Masahiro Tanemura and Koji Umeshita and Naoki Hiramatsu and Tetsuo Takehara and Yuichiro Doki and Masaki Mori",
year = "2010",
month = "9",
day = "15",
doi = "10.1002/jso.21633",
language = "English",
volume = "102",
pages = "308--314",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Effects of preceding interferon therapy on outcome after surgery for hepatitis C virus-related hepatocellular carcinoma

AU - Tomimaru, Yoshito

AU - Nagano, Hiroaki

AU - Eguchi, Hidetoshi

AU - Kobayashi, Shogo

AU - Marubashi, Shigeru

AU - Wada, Hiroshi

AU - Tanemura, Masahiro

AU - Umeshita, Koji

AU - Hiramatsu, Naoki

AU - Takehara, Tetsuo

AU - Doki, Yuichiro

AU - Mori, Masaki

PY - 2010/9/15

Y1 - 2010/9/15

N2 - Background and Objectives: Interferon (IFN) can eradicate hepatitis C virus (HCV)-RNA from serum and hepatic tissue, and suppress the development of hepatocellular carcinoma (HCC). Despite such effectiveness, HCC develops even in HCV patients successfully treated with IFN therapy. Methods: HCV-related HCC patients who underwent curative hepatectomy for HCC were divided into three groups according to preceding IFN for HCV infection therapy and the therapeutic effect: responders group (n=23), non-responders group (n=46), and no-IFN group (n=215). Postoperative outcome was retrospectively examined in the three groups. Results: AST and ALT were significantly lower in responders group than non-responders group (P<0.001, P=0.001) and no-IFN group (P=0.001, P=0.002). Platelet count was significantly higher in responders group than other groups (P=0.008, P=0.001). The percentage of cirrhotic patients in responders group was significantly lower than other groups (P=0.017, P=0.014). Multivariate analysis identified preceding IFN therapy to be associated with disease-free survival at marginal significance (P=0.086), and as a significant independent factor for overall survival (P=0.042). Conclusions: Preceding IFN therapy for HCV infection improves postoperative outcome in HCV-related HCC patients treated successfully with IFN.

AB - Background and Objectives: Interferon (IFN) can eradicate hepatitis C virus (HCV)-RNA from serum and hepatic tissue, and suppress the development of hepatocellular carcinoma (HCC). Despite such effectiveness, HCC develops even in HCV patients successfully treated with IFN therapy. Methods: HCV-related HCC patients who underwent curative hepatectomy for HCC were divided into three groups according to preceding IFN for HCV infection therapy and the therapeutic effect: responders group (n=23), non-responders group (n=46), and no-IFN group (n=215). Postoperative outcome was retrospectively examined in the three groups. Results: AST and ALT were significantly lower in responders group than non-responders group (P<0.001, P=0.001) and no-IFN group (P=0.001, P=0.002). Platelet count was significantly higher in responders group than other groups (P=0.008, P=0.001). The percentage of cirrhotic patients in responders group was significantly lower than other groups (P=0.017, P=0.014). Multivariate analysis identified preceding IFN therapy to be associated with disease-free survival at marginal significance (P=0.086), and as a significant independent factor for overall survival (P=0.042). Conclusions: Preceding IFN therapy for HCV infection improves postoperative outcome in HCV-related HCC patients treated successfully with IFN.

UR - http://www.scopus.com/inward/record.url?scp=77956588097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956588097&partnerID=8YFLogxK

U2 - 10.1002/jso.21633

DO - 10.1002/jso.21633

M3 - Article

C2 - 20589711

AN - SCOPUS:77956588097

VL - 102

SP - 308

EP - 314

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 4

ER -